Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Complement inhibition with Cinryze in severe traumatic brain injury
2020-000140-58Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in traumatic brain injury (TBI) comparing Cinryze with Placebo (2 arms). Primary endpoints: Safety of Cinryze 6000 IU in moderate and severe TBI and Efficacy of Cinryze 6000 IU in moderate and severe TBI. Started Feb 2020; status: active.
02
Drugs
c1-esterase inhibitor
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on 2020-000140-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000140-58.